KR880007521A - 항비루스성 화합물 - Google Patents

항비루스성 화합물 Download PDF

Info

Publication number
KR880007521A
KR880007521A KR870014274A KR870014274A KR880007521A KR 880007521 A KR880007521 A KR 880007521A KR 870014274 A KR870014274 A KR 870014274A KR 870014274 A KR870014274 A KR 870014274A KR 880007521 A KR880007521 A KR 880007521A
Authority
KR
South Korea
Prior art keywords
compound
hydrogen
group
hydroxy
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR870014274A
Other languages
English (en)
Korean (ko)
Inventor
제인 마틴 푸리포이 도로시
죠지 라힘 사드
Original Assignee
마이클 피터잭슨
더 웰컴 파운데이숀 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 마이클 피터잭슨, 더 웰컴 파운데이숀 리미티드 filed Critical 마이클 피터잭슨
Publication of KR880007521A publication Critical patent/KR880007521A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Silicon Polymers (AREA)
KR870014274A 1986-12-15 1987-12-14 항비루스성 화합물 Ceased KR880007521A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB868629892A GB8629892D0 (en) 1986-12-15 1986-12-15 Antiviral compounds
GB8629892 1986-12-15

Publications (1)

Publication Number Publication Date
KR880007521A true KR880007521A (ko) 1988-08-27

Family

ID=10609013

Family Applications (1)

Application Number Title Priority Date Filing Date
KR870014274A Ceased KR880007521A (ko) 1986-12-15 1987-12-14 항비루스성 화합물

Country Status (30)

Country Link
US (1) US5079235A (https=)
EP (3) EP0417560A1 (https=)
JP (2) JPS63165397A (https=)
KR (1) KR880007521A (https=)
CN (2) CN87108265A (https=)
AT (1) ATE88713T1 (https=)
AU (2) AU601529B2 (https=)
CA (1) CA1319143C (https=)
CS (3) CS275398B2 (https=)
DD (2) DD274766A5 (https=)
DE (1) DE3785651T2 (https=)
DK (2) DK654287A (https=)
ES (1) ES2054693T3 (https=)
FI (2) FI941523L (https=)
GB (1) GB8629892D0 (https=)
HU (4) HU200932B (https=)
IE (2) IE930471L (https=)
IL (3) IL95141A (https=)
LT (1) LT2064B (https=)
LV (1) LV5273A3 (https=)
MC (1) MC1882A1 (https=)
MX (1) MX9203216A (https=)
NO (1) NO167576C (https=)
NZ (1) NZ222898A (https=)
PH (2) PH24104A (https=)
PL (3) PL158050B1 (https=)
PT (1) PT86356B (https=)
RU (1) RU2036199C1 (https=)
SU (1) SU1731064A3 (https=)
ZA (1) ZA879382B (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU598946B2 (en) * 1987-06-24 1990-07-05 Howard Florey Institute Of Experimental Physiology And Medicine Nucleoside derivatives
US4954485A (en) * 1987-10-20 1990-09-04 Sanyo-Kokusaku Pulp Co., Ltd. 2',3'-dideoxy-4-thio-uridine derivatives, process for their preparation and antivirus agents using them
EP0346108A3 (en) * 1988-06-09 1991-04-24 The Wellcome Foundation Limited Anti-infective nucleosides
US5157114A (en) * 1988-08-19 1992-10-20 Burroughs Wellcome Co. 2',3'-dideoxy-3'-fluoro-5-ethyngluridine
GB8827339D0 (en) * 1988-11-23 1988-12-29 Wellcome Found Antiviral compounds
US5006646A (en) * 1989-02-22 1991-04-09 Yuki Gosei Kogyo Co., Ltd. Process for preparing 2'-deoxy-5-trifluoromethyl-beta-uridine
NZ234534A (en) * 1989-07-17 1994-12-22 Univ Birmingham Pyrimidine 4'-thionucleoside derivatives and their preparation; intermediates therefor
DD293498A5 (de) * 1989-07-20 1991-09-05 Zi Fuer Molekularbiologie Der Adw,De Verfahren zur herstellung eines mittels fuer die behandlung oder prophylaxe von hepatits-infektionen bei mensch und tier
US6337209B1 (en) 1992-02-26 2002-01-08 Glaxo Wellcome Inc. Molecular constructs containing a carcinoembryonic antigen regulatory sequence
GB8919607D0 (en) 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
GB9008696D0 (en) * 1990-04-18 1990-06-13 Wellcome Found Anti-viral compounds
GB9012899D0 (en) * 1990-06-09 1990-08-01 Wellcome Found Anti-hbv pyrimidine nucleoside
GB9014618D0 (en) * 1990-06-30 1990-08-22 Wellcome Found Process for the preparation of pyrimidine nucleosides
JP3094036B2 (ja) * 1990-07-19 2000-10-03 ザ ウエルカム ファウンデーション リミテッド 酵素不活性化剤
US5643913A (en) * 1990-07-19 1997-07-01 Glaxo Wellcome Inc. Pharmaceutical compositions of 5-substituted uracil compounds
GB9020930D0 (en) 1990-09-26 1990-11-07 Wellcome Found Pharmaceutical combinations
GB9104165D0 (en) * 1991-02-27 1991-04-17 Wellcome Found Novel entities for hiv therapy
GB9111580D0 (en) * 1991-05-30 1991-07-24 Wellcome Found Nucleoside derivative
US5646123A (en) * 1991-06-10 1997-07-08 Alberta Research Council Time dependent administration of oligosaccharide glycosides related to blood group determinants having a type I or type II core structure in reducing inflammation in a sensitized mammal arising form exposure to an antigen
US5580858A (en) * 1991-06-10 1996-12-03 Alberta Research Council Immunosuppressive and tolerogenic modified Lewisx compounds
HU207524B (en) * 1991-11-22 1993-04-28 Mta Koezponti Kemiai Kutato In Industrial process for producing 5-alkyl-2'-deoxy-beta-uridines with stereoselective synthesis
TW393513B (en) * 1991-11-26 2000-06-11 Isis Pharmaceuticals Inc Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
US6235887B1 (en) 1991-11-26 2001-05-22 Isis Pharmaceuticals, Inc. Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
US5484908A (en) * 1991-11-26 1996-01-16 Gilead Sciences, Inc. Oligonucleotides containing 5-propynyl pyrimidines
AU3222793A (en) * 1991-11-26 1993-06-28 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
WO1993024506A1 (en) * 1992-05-26 1993-12-09 Alberta Research Council IMMUNOSUPPRESSIVE AND TOLEROGENIC MODIFIED LEWISC AND LacNAc COMPOUNDS
CA2119315A1 (en) * 1993-03-18 1994-09-19 Tsujiaki Hata Nucleoside derivatives and anti-herpes composition
US6432924B1 (en) 1993-12-26 2002-08-13 East Carolina University Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase
DE69531729T2 (de) * 1994-12-13 2004-08-05 Taiho Pharmaceutical Co. Ltd. 3'-substuierte nukleosidderivate
KR19990076695A (ko) * 1995-12-22 1999-10-15 리차드 알. 이킨 시티딘 데아미나제 혹은 데옥시시티딘 데아미나제의 과발현과연관된 질병들을 치료하기 위한 활성제_및 방법
EP0878193A1 (en) * 1996-02-02 1998-11-18 Showa Shell Sekiyu K.K. Remedies for herpesvirus infection caused by herpesvirus and preventives for recurrence of the infection both containing triterpene derivatives as the active ingredient
CN1911237B (zh) * 1998-08-10 2010-09-15 艾丹尼克斯(开曼)有限公司 用于治疗乙型肝炎的β-L-2＇-脱氧-核苷
US6653318B1 (en) 1999-07-21 2003-11-25 Yale University 5-(E)-Bromovinyl uracil analogues and related pyrimidine nucleosides as anti-viral agents and methods of use
US7019129B1 (en) 2000-05-09 2006-03-28 Biosearch Technologies, Inc. Dark quenchers for donor-acceptor energy transfer
AU2002360697B2 (en) * 2001-12-20 2009-04-23 Beth Israel Deaconess Medical Center Treatment of EBV and KHSV infection and associated abnormal cellular proliferation
NZ555176A (en) 2004-12-03 2010-03-26 Adherex Technologies Inc Methods for administering DPD inhibitors in combination with 5-FU and 5-FU prodrugs
EP2268608A4 (en) 2008-04-01 2012-01-11 Biosearch Technologies Inc PROBES FOR STABILIZED NUCLEIC ACID DARK QUENCHER FLUOROPHORE
CN101768197A (zh) * 2008-12-29 2010-07-07 北京德众万全药物技术开发有限公司 一种奈拉滨的制备方法
CA2777546C (en) 2009-10-14 2019-11-05 Elion Oncology Llc Treating neurotoxicity associated with combinations of 5-fu or its prodrugs and dpd inhibitors
WO2015153510A1 (en) * 2014-03-30 2015-10-08 Cepheid Modified cytosine polynucleotide oligomers and methods

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1601020A (en) 1978-04-24 1981-10-21 Stichting Grega Vzw 2'-deoxy-5 (2-halogenovinyl)-uridines
US4211773A (en) * 1978-10-02 1980-07-08 Sloan Kettering Institute For Cancer Research 5-Substituted 1-(2'-Deoxy-2'-substituted-β-D-arabinofuranosyl)pyrimidine nucleosides
US4247544A (en) * 1979-07-02 1981-01-27 The Regents Of The University Of California C-5 Substituted uracil nucleosides
US4267171A (en) * 1979-07-02 1981-05-12 The Regents Of The University Of California C-5 Substituted cytosine nucleosides
US4274544A (en) * 1980-03-11 1981-06-23 The Continental Group, Inc. Single-piece plastic closure having integral seal forming means
EP0082668A1 (en) * 1981-12-18 1983-06-29 Beecham Group Plc 5-(2-Halogenovinyl)-2'-deoxyuridine derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in treating viral infections
EP0082667A1 (en) * 1981-12-18 1983-06-29 Beecham Group Plc Pharmaceutical compositions
EP0095294A1 (en) * 1982-05-22 1983-11-30 Beecham Group Plc Deoxyuridine compounds, methods for preparing them and their use in medicine
EP0097039A1 (en) * 1982-06-16 1983-12-28 Beecham Group Plc 5-(E-2-halovinyl)-2'-deoxyuridine derivatives, processes for their preparation, pharmaceutical compositions containing them, and their use in treating viral infections
GB8517402D0 (en) * 1985-07-10 1985-08-14 Wellcome Found Treatment of viral infections
EP0217580A3 (en) * 1985-09-17 1990-11-07 The Wellcome Foundation Limited Therapeutic nucleosides
SE8701605D0 (sv) * 1987-04-16 1987-04-16 Astra Ab Novel medicinal compounds

Also Published As

Publication number Publication date
HU207735B (en) 1993-05-28
SU1731064A3 (ru) 1992-04-30
FI941523A7 (fi) 1994-03-31
FI941523A0 (fi) 1994-03-31
DE3785651D1 (de) 1993-06-03
EP0486477A3 (en) 1992-06-17
JPS63165397A (ja) 1988-07-08
NO167576B (no) 1991-08-12
FI875487A7 (fi) 1988-06-16
HU199867B (en) 1990-03-28
EP0417560A1 (en) 1991-03-20
IL84810A0 (en) 1988-06-30
CS275402B6 (en) 1992-02-19
AU5989090A (en) 1990-11-08
DK654287A (da) 1988-06-16
IE930470L (en) 1988-06-15
DK168323B1 (da) 1994-03-14
US5079235A (en) 1992-01-07
CN87108265A (zh) 1988-07-13
NO167576C (no) 1991-11-20
HU202112B (en) 1991-02-28
DE3785651T2 (de) 1993-11-11
MC1882A1 (fr) 1989-01-24
AU626041B2 (en) 1992-07-23
FI941523L (fi) 1994-03-31
PH24870A (en) 1990-12-26
EP0272065A3 (en) 1988-11-17
PL160322B1 (pl) 1993-02-26
PT86356A (en) 1988-01-01
DK169991A (da) 1991-10-04
PL158050B1 (pl) 1992-07-31
CS916187A2 (en) 1991-02-12
FI875487A0 (fi) 1987-12-14
ES2054693T3 (es) 1994-08-16
CS767588A3 (en) 1991-02-12
PH24104A (en) 1990-03-05
RU2036199C1 (ru) 1995-05-27
JPH03141292A (ja) 1991-06-17
PT86356B (pt) 1990-11-07
DD274766A5 (de) 1990-01-03
EP0272065B1 (en) 1993-04-28
NZ222898A (en) 1990-12-21
CS342591A3 (en) 1992-04-15
CS275398B2 (en) 1992-02-19
DK169991D0 (da) 1991-10-04
IE930471L (en) 1988-06-15
PL160321B1 (pl) 1993-02-26
GB8629892D0 (en) 1987-01-28
IL95141A (en) 1992-05-25
HUT46336A (en) 1988-10-28
EP0486477A2 (en) 1992-05-20
HU200932B (en) 1990-09-28
IL84810A (en) 1992-05-25
AU601529B2 (en) 1990-09-13
LT2064B (lt) 1993-06-15
PL269462A1 (en) 1989-06-26
EP0272065A2 (en) 1988-06-22
IL95141A0 (en) 1991-06-10
ATE88713T1 (de) 1993-05-15
DD264924A5 (de) 1989-02-15
NO875209D0 (no) 1987-12-14
CA1319143C (en) 1993-06-15
AU8252187A (en) 1988-06-16
ZA879382B (en) 1989-08-30
JPH0378370B2 (https=) 1991-12-13
DK654287D0 (da) 1987-12-14
PL277927A1 (en) 1989-08-21
LV5273A3 (lv) 1993-10-10
NO875209L (no) 1988-06-16
CN1080292A (zh) 1994-01-05
PL277926A1 (en) 1989-08-21
HU903829D0 (en) 1990-11-28
MX9203216A (es) 1992-07-01

Similar Documents

Publication Publication Date Title
KR880007521A (ko) 항비루스성 화합물
HUT61989A (en) Process for producing 2-deoxy-2,3-didehydro-n-acetylneuraminic acid derivatives and analogs, as well as pharmaceutical compositions comprising same as active ingredient
EP0371731A3 (en) Quinazolinone derivatives
IL101203A0 (en) Cyclic urea derivatives,their preparation and pharmaceutical compositions containing them
KR890003761A (ko) 치료학적 아시클릭 뉴클레오시드
KR890003731A (ko) 인돌 유도체
EA200100298A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ С РЕГУЛИРУЕМЫМ ВЫСВОБОЖДЕНИЕМ, СОДЕРЖАЩИЕ ИНГИБИТОР cGMP-ФОСФОДИЭСТЕРАЗЫ-5
GB2122618B (en) Purine derivatives
KR880006193A (ko) 피페리딘 화합물 및 그의 제조 및 용도
FR2361901A1 (fr) Derives de substitution de nucleotides et medicament contenant ces substances
KR910018398A (ko) 3당류 유니트(unit)를 함유하는 탄수화물 유도체
TNSN90021A1 (fr) Procede de preparation de tetrahydroimidazo (1,4) benzodiazepin -2- thiones antivirales
ES8403494A1 (es) "un procedimiento para la preparacion de derivados de s-adenosilmetionina".
TNSN89039A1 (fr) Tetrahydroimidazo(1,4)benzodiazepin-2-ones antivirales
KR880007080A (ko) 제약학적 생성물
US5028595A (en) Method for preventing AIDS in a subject or treating a subject infected with the AIDS virus
KR890008160A (ko) 약학적 뉴클레오시드
KR900004736A (ko) 신규한2'-할로메틸리덴, 2'-에테닐리덴 및 2'-에티닐 아데노신 유도체
KR900011468A (ko) 치료용 뉴클레오시드
SE8007171L (sv) Forfarande for framstellning av en farmaceutisk komposition omfattande substituerade difenylsulfider
IL65787A (en) Antiviral pharmaceutical compositions containing alpha,alpha-dialkyl-adamantylamines
EP0307914A2 (en) Pharmaceutical compositions containing a dideoxynucleoside
US4038479A (en) Amino purine derivatives
KR900012925A (ko) 인돌 유도체
KR970704723A (ko) 항염증제로서 유용한 디히드로벤조푸란 및 관련 화합물(dihydrobenzofuran and related compounds useful as anti-inflammatory agents)

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19871214

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19920623

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19871214

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19950724

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 19951023

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 19950724

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I